NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis $2.57 +0.12 (+4.90%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.71 +0.14 (+5.45%) As of 05/2/2025 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Achieve Life Sciences Stock (NASDAQ:ACHV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Achieve Life Sciences alerts:Sign Up Key Stats Today's Range$2.46▼$2.6450-Day Range$1.98▼$3.1452-Week Range$1.84▼$5.59Volume164,559 shsAverage Volume187,749 shsMarket Capitalization$89.14 millionP/E RatioN/ADividend YieldN/APrice Target$14.33Consensus RatingStrong Buy Company OverviewAchieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Read More… Achieve Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreACHV MarketRank™: Achieve Life Sciences scored higher than 39% of companies evaluated by MarketBeat, and ranked 564th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingAchieve Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAchieve Life Sciences has received no research coverage in the past 90 days.Read more about Achieve Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.17) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -2.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Achieve Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.42% of the float of Achieve Life Sciences has been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Achieve Life Sciences has recently decreased by 12.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.42% of the float of Achieve Life Sciences has been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in Achieve Life Sciences has recently decreased by 12.89%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Achieve Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows1 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,900.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 33.52% of the stock of Achieve Life Sciences is held by institutions.Read more about Achieve Life Sciences' insider trading history. Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHV Stock News HeadlinesAchieve Life Sciences Reports Positive Results from ORCA-3 Trial of Cytisinicline for Smoking CessationApril 23, 2025 | nasdaq.comAchieve Life Sciences announces publication of results from Phase 3 ORCA-3 trialApril 22, 2025 | finance.yahoo.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.May 4, 2025 | Paradigm Press (Ad)Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal MedicineApril 21, 2025 | globenewswire.comJonesTrading Keeps Their Buy Rating on Achieve Life Sciences (ACHV)April 2, 2025 | markets.businessinsider.comD-Wave Claims to Achieve ‘Quantum Supremacy’ — Some Researchers DisagreeMarch 30, 2025 | techrepublic.comAchieve Life Sciences, Inc. (ACHV): A Bull Case TheoryMarch 20, 2025 | insidermonkey.comACHV: 2Q:25 NDA SubmissionMarch 12, 2025 | msn.comSee More Headlines ACHV Stock Analysis - Frequently Asked Questions How have ACHV shares performed this year? Achieve Life Sciences' stock was trading at $3.52 on January 1st, 2025. Since then, ACHV shares have decreased by 27.0% and is now trading at $2.57. View the best growth stocks for 2025 here. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Tuesday, March, 11th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.06. Read the conference call transcript. When did Achieve Life Sciences' stock split? Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings3/11/2025Today5/04/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHV CIK949858 Webachievelifesciences.com Phone(604) 210-2217Fax425-686-1600Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+457.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.30% Return on Assets-65.20% Debt Debt-to-Equity Ratio0.31 Current Ratio6.78 Quick Ratio6.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-36.71Miscellaneous Outstanding Shares34,685,000Free Float33,702,000Market Cap$89.14 million OptionableOptionable Beta1.59 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ACHV) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredAI Boom Takes a Shocking Turn…What 99% of Investors are Missing in AI I believe it could be worth a fortune in the near future, yet hardl...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.